Curi RMB Capital Opposes Taisho Pharmaceutical HD's Management Buyout
Curi RMB Capital opposes the management buyout (“the MBO”) of Taisho Pharmaceutical Holdings Co., Ltd. (4581 JP, TSE Standard, “Taisho”) because we believe the MBO is unfair and ignores the interests of minority shareholders.
- Curi RMB Capital opposes the management buyout (“the MBO”) of Taisho Pharmaceutical Holdings Co., Ltd. (4581 JP, TSE Standard, “Taisho”) because we believe the MBO is unfair and ignores the interests of minority shareholders.
- Curi RMB Capital plans to vote against the buyout and related resolutions at the extraordinary general meeting of shareholders that will be held by Taisho next month.
- Curi RMB Capital believes the intrinsic value of Taisho should be no less than 10,132 yen per share, which is Taisho's book value per share as of September 30th, 2023.
- Curi RMB Capital believes the MBO was not carried out fairly and plans to oppose the MBO and its related resolutions at the upcoming extraordinary general meeting of shareholders held by Taisho in March.